EUCTR2018-002130-20-GB进行中（未招募）1 期
Research on Efficacy of Teriparatide use in the Return of recruits to Normal duty. - Study of Teriparatide in Stress Fracture Healing: RETUR
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Signed informed consent and able to comply with protocol;
- •2)Aged 18 to 40 years;
- •3)Lower limb stress fracture, confirmed by MRI scan;
- •4)Undergoing phase 1 or 2 training within an Army training establishment;
- •5)Baseline blood tests within reference range (see table 3 for more details). Minor abnormalities will be assessed by the PI. Patients will still be eligible if these are felt to be of no clinical importance and this decision is documented by the PI;
- •6)Participant is able to adhere to visit requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 136
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1)Hypersensitivity to the active Parathyroid Hormone substance or any of the excipients listed in the SPC.
- •2)Pre-existing hypercalcaemia
- •3)Patients with skeletal malignancies or bone metastases.
- •4)Any contraindications that would prevent the participant from undergoing an MRI scan.
- •5)Concurrent therapy that, in the investigators opinion, would interfere with the evaluation of the safety or efficacy of the study medication.
- •6)Pregnancy, suspected pregnancy or breastfeeding. Female participants must have a negative serum pregnancy test at screening and be willing and able to use a birth control method which may be considered as highly effective”, as per the Clinical Trial Facilitation Group (CTFG) guidance.*
- •7)Severe renal impairment. Participants with moderate renal impairment will be treated with caution at the Principal Investigator’s discretion and in accordance with the SmPC.
- •8)Metabolic bone diseases including hyperparathyroidism and Paget's disease of the bone.
- •9)Unexplained elevations of alkaline phosphatase.
- •10)Prior external beam or implant radiation therapy to the skeleton.
- •11)Patients participating in a concurrent drug trial.
- •12)Presentation with open epiphyses during the diagnostic MRI scan.
- •13)Participants with depression, as identified by completion of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Baseline.
- •**As per the CTFG guidance and for the purposes of this trial, a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12-months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
- •In accordance with CTFG guidance, methods that can achieve a failure rate of less than 1% per year when used consistently and correctly, are considered as highly effective” birth control methods. Such methods include:
- •- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (either oral, intravaginal or transdermal);
- •- Progestogen-only hormonal contraception associated with inhibition of ovulation (either oral, injectable or implantable);
- •- Intrauterine device (IUD);
- •- Intrauterine hormone-releasing system (IUS);
- •- Bilateral tubal occlusion;
- •- Vasectomised partner;
- •- Sexual abstinence. (Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated for the duration of the participant’s treatment period during the trial and the preferred and usual lifestyle of the participant.)
研究者
相似试验
已完成
3 期
A clinical trial with Teriparatide: a recombinant human parathyroid hormone) and Calcium and Vitamin D Supplementation in Post-menopausal Women with Osteoporosis.CTRI/2010/091/000242SV Ltd B S D Marg, Govandi,Mumbai 400 088Phone: (022) 2556 4048; Fax : (022) 2558 402580
已完成
Unknown
Teriparatide in Post-op Rotator Cuff HealingArthroscopic rotator cuff repair.Injury of muscle(s) and tendon(s) of the rotator cuff of shoulderS46.0IRCT20220809055649N1Tehran University of Medical Sciences50
已完成
不适用
The effect of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral headontraumatic osteonecrosis of the femoral headJPRN-UMIN000017582Department of Orthopaedic Surgery, Hokkaido University Graduate School of Medicine100
已完成
不适用
Evaluation of the efficacy of teriparatide for distal radial fracture repair after plate fixation in osteoporotic patients:A prospective randomized control study.osteoporosisJPRN-UMIN000015903Yokohama City University Medical Center20
进行中（未招募）
不适用
Estudio para evaluar el efecto de Teriparatida comparado con Risedronato en el dolor de espalda de las mujeres postmenopausicas con fracturas vertebrales osteoporóticas”The Effect of Teriparatide Compared with Risedronate on Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures - GHCYEUCTR2005-005258-29-ESilly S.A.1,638